GIO 2
Alternative Names: GIO-2Latest Information Update: 04 Dec 2024
Price :
$50 *
At a glance
- Originator GIO Therapeutics
- Class Anti-inflammatories; Antineoplastics
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer; Inflammation
Most Recent Events
- 25 Oct 2024 GIO 2 is available for licensing as of 25 Oct 2024. https://www.giotherapeutics.com/
- 24 Oct 2024 Early research in Cancer in Switzerland (unspecified route) prior to October 2024 (Cumulus Oncology Therapeutics Pipeline, October 2024) (GIO Therapeutics Pipeline, October 2024)
- 24 Oct 2024 Early research in Inflammation in Switzerland (unspecified route) prior to October 2024 (Cumulus Oncology Therapeutics Pipeline, October 2024) (GIO Therapeutics Pipeline, October 2024)